Results 81 to 90 of about 2,243,647 (283)

The interaction between UBR7 and PRMT5 drives PDAC resistance to gemcitabine by regulating glycolysis and immune microenvironment

Cell Death and Disease
Pancreatic ductal adenocarcinoma (PDAC) is a common malignant tumor of the digestive tract. Although gemcitabine and other therapeutic agents are effective in patients with advanced and metastatic pancreatic cancer, drug resistance has severely limited ...
Maoxiao Feng, Qinlian Jiao, Yidan Ren, Xiaoyan Liu, Zihan Gao, Zhengjun Li, Yunshan Wang, Miaoqing Zhao, Lei Bi   +8 more
doaj   +1 more source

Coixenolide Enhances Antitumor Immunity of Cytotoxic CD8+ T Cells by Inhibiting S100A8/A9‐CD36 Axis in Obesity‐Associated Pancreatic Adenocarcinoma

Advanced Science, EarlyView.
Pancreatic adenocarcinoma (PAAD) remains highly lethal with limited treatment options. This study demonstrates that coixenolide, a bioactive compound from Coix lacryma‐jobi L. and a key component of the clinically approved Kanglaite injection, exhibits enhanced antitumor efficacy in high‐fat diet (HFD)‐induced obese mice bearing PAAD tumors compared to
Kaidi Chen, Rong Chen, Wei Li, Bin Song, Ruiying Zhang, Lewei Dai, Yuwei Qi, Ruqian Chen, Yifan Xu, Hangbin Li, Jingyi Huang, Fangping Wu, Jianan Peng, Xinyu Wang, Yang Xiong, Chaofeng Mu, Guilin Cheng, Zhaoshen Li, Shanming Ruan, Lei Huang, Mancang Gu   +20 more
wiley   +1 more source

Clinical application and drug resistance mechanism of gemcitabine

Frontiers in Cell and Developmental Biology
Gemcitabine, as a nucleoside analog, exerts a broad-spectrum antitumor effect by interfering with DNA synthesis, but its clinical application is limited by drug resistance. The drug resistance mechanism involves metabolic abnormalities (such as downregulation of deoxycytidine kinase (dCK), nucleoside transporter hENT1 deficiency), enhanced DNA repair ...
Zhang, Xuanrui, Qi, Bing, Chen, Jing
openaire   +2 more sources

Cholesterol esterification inhibition and gemcitabine synergistically suppress pancreatic ductal adenocarcinoma proliferation. [PDF]

PLoS ONE, 2018
Recent advances have recognized metabolic reprogramming as an underlying mechanism for cancer drug resistance. However, the role of cholesterol metabolism in drug resistance remain elusive. Herein, we report an increased accumulation of cholesteryl ester
Junjie Li, Xiaochao Qu, Jie Tian, Jian-Ting Zhang, Ji-Xin Cheng   +4 more
doaj   +1 more source

Chemoproteomic Identification of AKT2 as a Paclitaxel‐Binding Protein via C─C Bond‐Linked Probe PTX‐4 in Paclitaxel‐Resistant Breast Cancer

Advanced Science, EarlyView.
ABSTRACT Breast cancer remains one of the most prevalent malignancies among women, and taxane‐based chemotherapies such as paclitaxel and docetaxel are central to standard treatment regimens. However, drug resistance in breast cancer limits therapeutic efficacy and contributes to recurrence and metastasis.
Kai Wang, Yuqing Yuan, Wei Shen, Xiuxiu Yang, Xiaokang Wu, Haihua Zhou, Yi Hu, Qing Zhu   +7 more
wiley   +1 more source

ANXA2+ Small Extracellular Vesicles Drive Chemoresistance in Anaplastic Thyroid Cancer by Promoting XRCC5 Lactylation and Enhancing Non‐Homologous End‐Joining Repair

Advanced Science, EarlyView.
ANXA2+ sEVs promote cisplatin resistance in ATC by stabilizing the SRC/LDHA interaction, increasing LDHA phosphorylation and activity, and lactate production. Elevated lactate levels promote KAT5‐mediated lactylation of XRCC5 at lysine 265, enhancing its binding to XRCC6.
Shanshan Su, YiShan Xiong, Yuxuan Liang, Xiang Min, Daofeng Dai   +4 more
wiley   +1 more source

Epigenetic Activation of the CMTM6‐IGF2BP1‐EP300 Positive Feedback Loop Drives Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma

Advanced Science
Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with a dismal prognosis. Gemcitabine‐based chemotherapy has emerged as a first‐line treatment for PDAC.
Ying‐Qin Zhu, Yue Huang, Yin‐Hao Shi, Chen‐Song Huang, Guang‐Yin Zhao, Zhi‐De Liu, Ming‐Jian Ma, Jing‐Yuan Ye, Xiang Xu, Qi Liu, Xi‐Tai Huang, Jie‐Qin Wang, Qiong‐Cong Xu, Xiao‐Yu Yin   +13 more
doaj   +1 more source

Elevated PAF1-RAD52 axis confers chemoresistance to human cancers

Cell Reports, 2023
Summary: Cisplatin- and gemcitabine-based chemotherapeutics represent a mainstay of cancer therapy for most solid tumors; however, resistance limits their curative potential.
Sanchita Rauth, Koelina Ganguly, Pranita Atri, Seema Parte, Rama Krishna Nimmakayala, Venkatesh Varadharaj, Palanisamy Nallasamy, Raghupathy Vengoji, Ayoola O. Ogunleye, Imayavaramban Lakshmanan, Ramakanth Chirravuri, Mika Bessho, Jesse L. Cox, Jason M. Foster, Geoffrey A. Talmon, Tadayoshi Bessho, Apar Kishor Ganti, Surinder K. Batra, Moorthy P. Ponnusamy   +18 more
doaj   +1 more source

A Spatially Directed Microneedle Patch Enables Intratumoral Co‐Delivery of FOLFIRINOX, Surufatinib, and Anti‐PD‐1 for Chemo‐Immunotherapy of Pancreatic Ductal Adenocarcinoma

Advanced Science, EarlyView.
A double‐layered shell‐core microneedle patch is developed to co‐deliver FOLFIRINOX, surufatinib, and anti‐PD‐1 for localized chemo‐immunotherapy of PDAC. This strategy achieves sustained tumor suppression, reduces metastasis, and reprograms the TME by enhancing CD8+ T‐cell infiltration and inhibiting Tregs and M2 macrophages infiltration, while ...
Tingting Kong, Ximo Xu, Xiao Zhang, Chuntao Wu, Zhengjun Qiu, Beiyuan Hu, Zihao Qi, Qiang Tian, Yuqin Yang, Hanguang Dong, Fei Wu, Tuo Jin, Yan Zheng, Jiang Long   +13 more
wiley   +1 more source

Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia. [PDF]

, 2011
Irinotecan-containing regimens are known to be active and tolerable in patients with non-small cell lung cancer (NSCLC). A randomized phase II trial was conducted to evaluate the efficacy of irinotecan plus paclitaxel or gemcitabine for previously ...
Akitoshi Kinoshita, Kasai, Takashi, Nagashima, Seiji, Soejima, Yoshifumi, Yoshifumi Soejima, Tsukamoto, Kazuhiro, Fukuda, Minoru, Katsumi Nakatomi, Takatani, Hiroshi, Shigeru Kohno, Minoru Fukuda, Seiji Nagashima, Fukuda, Masaaki, Kazuhiro Tsukamoto, Yoichi Nakamura, Mikio Oka, Masuda, Noriyuki, Nakamura, Yoichi, Hiroshi Soda, Hiroshi Takatani, Oka, Mikio, Nakatomi, Katsumi, Masaaki Fukuda, Noriyuki Masuda, Kohno, Shigeru, Kinoshita, Akitoshi, Soda, Hiroshi, Takashi Kasai   +27 more
core   +1 more source